Do analysts rate APLM or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, APLM or TPST?

Apollomics has higher revenue and earnings than Tempest Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.89 -$10.94M N/A N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is APLM or TPST more profitable?

Apollomics' return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Tempest Therapeutics N/A -576.56% -134.99%

Do analysts prefer MCRB or TPST?

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 348.55%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Seres Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to MCRB or TPST?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Tempest Therapeutics' score of 0.23 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TIL or TPST?

Instil Bio presently has a consensus price target of $7.00, indicating a potential downside of 3.31%. Given Instil Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Instil Bio is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, TIL or TPST?

Instil Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is TIL or TPST more profitable?

Instil Bio's return on equity of -26.78% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Tempest Therapeutics N/A -576.56% -134.99%

Do analysts recommend TPST or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, TPST or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is TPST or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Black Hawk Acquisition N/A N/A N/A

Does the media prefer TPST or BKHA?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat Tempest Therapeutics' score of 0.23 indicating that Black Hawk Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TPST or TVGN?

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,188.49%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, TPST or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is TPST or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Tevogen Bio N/A N/A -468.32%

Does the media prefer TPST or TVGN?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Tevogen Bio. Tempest Therapeutics' average media sentiment score of 0.23 beat Tevogen Bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tempest Therapeutics (TPST) Competitors

$0.92 -0.08 (-7.80%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+1.41%)

As of 05:21 AM Eastern

Compare

TPST vs. APLM, MCRB, TIL, BKHA, and TVGN

Should you buy Tempest Therapeutics stock or one of its competitors? Tempest Therapeutics's main competitors and comparable companies include Apollomics (APLM), Seres Therapeutics (MCRB), Instil Bio (TIL), Black Hawk Acquisition (BKHA), and Tevogen Bio (TVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tempest Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Apollomics has higher revenue and earnings than Tempest Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, indicating that its stock price is 268% less volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Tempest Therapeutics	N/A	-576.56%	-134.99%

In the previous week, Tempest Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Tempest Therapeutics and 0 mentions for Apollomics. Tempest Therapeutics' average media sentiment score of 0.23 beat Apollomics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Tempest Therapeutics	Neutral

Summary

Apollomics and Tempest Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Tempest Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Tempest Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Tempest Therapeutics	N/A	-576.56%	-134.99%

In the previous week, Tempest Therapeutics had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Tempest Therapeutics' score of 0.23 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 348.55%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Seres Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Seres Therapeutics has higher revenue and earnings than Tempest Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	48.21	$5.70M	-$2.43	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Seres Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, suggesting that its share price is 268% less volatile than the broader market.

Summary

Seres Therapeutics beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Instil Bio presently has a consensus price target of $7.00, indicating a potential downside of 3.31%. Given Instil Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Instil Bio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Instil Bio's return on equity of -26.78% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Tempest Therapeutics	N/A	-576.56%	-134.99%

In the previous week, Tempest Therapeutics had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for Tempest Therapeutics and 0 mentions for Instil Bio. Tempest Therapeutics' average media sentiment score of 0.23 beat Instil Bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
Tempest Therapeutics	Neutral

Instil Bio has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.68, suggesting that its stock price is 268% less volatile than the broader market.

Instil Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

Summary

Instil Bio beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Tempest Therapeutics (NASDAQ:TPST) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat Tempest Therapeutics' score of 0.23 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Hawk Acquisition's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Black Hawk Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Tempest Therapeutics has a beta of -1.68, indicating that its share price is 268% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

22.5% of Tempest Therapeutics shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Tempest Therapeutics and Black Hawk Acquisition tied by winning 4 of the 8 factors compared between the two stocks.

How does Tempest Therapeutics compare to Tevogen Bio?

Tempest Therapeutics (NASDAQ:TPST) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,188.49%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tempest Therapeutics has a beta of -1.68, indicating that its stock price is 268% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Tevogen Bio. Tempest Therapeutics' average media sentiment score of 0.23 beat Tevogen Bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.5% of Tempest Therapeutics shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tevogen Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Tevogen Bio	N/A	N/A	-468.32%

Summary

Tempest Therapeutics beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.54M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.22	13.88	274.09	25.69
Price / Sales	N/A	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.68	15.40	10.47	6.32
Net Income	-$26.26M	-$22.82M	$3.49B	$359.73M
7 Day Performance	3.02%	-1.74%	-0.68%	0.17%
1 Month Performance	-16.18%	-6.20%	-3.18%	-3.27%
1 Year Performance	-89.98%	30.64%	15.12%	5.58%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.171 of 5 stars	$0.92 -7.8%	N/A	-89.6%	$16.54M	N/A	N/A	4	News Coverage
APLM Apollomics	1.1627 of 5 stars	$23.92 +3.1%	N/A	+25.1%	$50.96M	$8.50M	N/A	45	Gap Down
MCRB Seres Therapeutics	3.0551 of 5 stars	$4.73 -5.6%	$17.00 +259.4%	-78.4%	$50.32M	$790K	N/A	330
TIL Instil Bio	0.7127 of 5 stars	$7.45 +0.9%	$7.00 -6.0%	-59.0%	$50.05M	N/A	N/A	410	Positive News High Trading Volume
BKHA Black Hawk Acquisition	N/A	$11.79 -1.7%	N/A	+9.0%	$49.80M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. APLM, MCRB, TIL, BKHA, and TVGN

How does Tempest Therapeutics compare to Apollomics?

Summary

How does Tempest Therapeutics compare to Seres Therapeutics?

Summary

How does Tempest Therapeutics compare to Instil Bio?

Summary

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Summary

How does Tempest Therapeutics compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. APLM, MCRB, TIL, BKHA, and TVGN

How does Tempest Therapeutics compare to Apollomics?

Which has better valuation & earnings, APLM or TPST?

Do analysts rate APLM or TPST?

Which has more risk and volatility, APLM or TPST?

Do insiders and institutionals believe in APLM or TPST?

Is APLM or TPST more profitable?

Does the media refer more to APLM or TPST?

Summary

How does Tempest Therapeutics compare to Seres Therapeutics?

Is MCRB or TPST more profitable?

Does the media refer more to MCRB or TPST?

Do analysts prefer MCRB or TPST?

Which has better earnings and valuation, MCRB or TPST?

Do institutionals and insiders have more ownership in MCRB or TPST?

Which has more volatility and risk, MCRB or TPST?

Summary

How does Tempest Therapeutics compare to Instil Bio?

Do analysts prefer TIL or TPST?

Do institutionals & insiders believe in TIL or TPST?

Is TIL or TPST more profitable?

Does the media prefer TIL or TPST?

Which has more volatility & risk, TIL or TPST?

Which has preferable valuation & earnings, TIL or TPST?

Summary

How does Tempest Therapeutics compare to Black Hawk Acquisition?

Does the media prefer TPST or BKHA?

Is TPST or BKHA more profitable?

Do analysts recommend TPST or BKHA?

Which has preferable earnings and valuation, TPST or BKHA?

Which has more volatility & risk, TPST or BKHA?

Do institutionals & insiders have more ownership in TPST or BKHA?

Summary

How does Tempest Therapeutics compare to Tevogen Bio?

Do analysts prefer TPST or TVGN?

Which has more risk & volatility, TPST or TVGN?

Does the media prefer TPST or TVGN?

Do insiders and institutionals have more ownership in TPST or TVGN?

Which has better earnings & valuation, TPST or TVGN?

Is TPST or TVGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools